Last reviewed · How we verify
RGD Peptide
At a glance
| Generic name | RGD Peptide |
|---|---|
| Sponsor | Minia University |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- RGD With Minimally Invasive Non-Surgical Technique in Treatment of Periodontal Intrabony Defect (NA)
- The Use of Adhesion Molecule Loaded Hydrogel With Minimally Invasive Surgical Technique in Treatment of Periodontal Intrabony Defect (PHASE1, PHASE2)
- Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects (PHASE2)
- Targeted PET/CT and PET/MRI Imaging of Vascular Inflammation (PHASE2)
- RGD PET/CT Imaging in COVID-19 Patients
- 18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy (PHASE1, PHASE2)
- A Study of 99mTc-3PRGD2 Injection in Healthy Volunteers (PHASE1)
- DNX-2401 With Interferon Gamma (IFN-γ) for Recurrent Glioblastoma or Gliosarcoma Brain Tumors (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- RGD Peptide CI brief — competitive landscape report
- RGD Peptide updates RSS · CI watch RSS
- Minia University portfolio CI